Mutations in the epidermal growth factor receptor (EGFR) are the most common targeted mutations in NSCLC, with EGFR exon 19 deletion and exon 21 Leu858Arg point mutations accounting for approximately 85% of somatic EGFR alterations (Castellanos et al., 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.